Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies.
Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies.
复制标题
DOI：
10.14218/jcth.2017.00050
复制
发表时间：
2018-06-28
影响因子：
3.6
通讯作者：
Cholankeril G
中科院分区：
文献类型：
--
作者：
Snyder HS;Sakaan SA;March KL;Siddique O;Cholankeril R;Cummings CD;Gadiparthi C;Satapathy SK;Ahmed A;Cholankeril G
非酒精性脂肪性肝病(NAFLD)是最常见的肝病原因，影响着大约7500万至1亿美国人。与非糖尿病患者相比，并发NAFLD和2型糖尿病的患者进展为晚期纤维化和非酒精性脂肪性肝炎的风险更高。改变生活方式，包括减肥，仍然是治疗NAFLD的主要方法，因为目前还没有针对这种疾病状态的药物。旨在改善胰岛素敏感性和减少胰岛素产生的抗糖尿病药物治疗已经被研究，以确定它们在减缓NAFLD进展方面的潜在作用。在这篇综述中，我们着重于围绕抗糖尿病药物及其改善NAFLD患者疾病进展的能力的证据。
Non-alcoholic fatty liver disease (NAFLD), the most common cause of liver disease, affects approximately 75 to 100 million Americans. Patients with concurrent NAFLD and type 2 diabetes mellitus have a higher risk of progressing to advanced fibrosis and non-alcoholic steatohepatitis compared to non-diabetics. Lifestyle modifications, including weight loss, remain the mainstay of treatment for NAFLD, as there are no medications currently indicated for this disease state. Anti-diabetic pharmacologic therapies aimed at improving insulin sensitivity and decreasing insulin production have been studied to determine their potential role in slowing the progression of NAFLD. In this review, we focus on the evidence surrounding anti-diabetic medications and their ability to improve disease progression in patients with NAFLD.